MétaCan
Menu
Back to cohort
Record W4213217478 · doi:10.1097/der.0000000000000845

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

2022· review· en· W4213217478 on OpenAlexaffvenue
Aaron M. Drucker, Megan Lam, Carsten Flohr, Jacob P. Thyssen, Kenji Kabashima, Robert Bissonnette, Ncoza C. Dlova, Valéria Aoki, Max Chen, J T H T Yu, Jie Wei Zhu, Robert Micieli, Audrey Nosbaum

Bibliographic record

VenueDermatitis · 2022
Typereview
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsInnovaderm (Canada)University of TorontoMcMaster UniversityWomen's College Hospital
FundersMedacOno PharmaceuticalMitsubishi Tanabe Pharma CorporationLundbeckfondenNational Eczema AssociationDermiraFundação de Amparo à Pesquisa do Estado de São PauloIncyteTaiho PharmaceuticalRegeneron PharmaceuticalsLes Laboratories Pierre FabreCelgeneEuropean CommissionSanofiL'Oreal USAPfizerLEO PharmaTorii PharmaceuticalGaldermaEli Lilly and Company
KeywordsMedicineDupilumabSystemic therapyAtopic dermatitisAzathioprineMEDLINEPopulationObservational studyComorbidityDiseaseSystemic vasculitisDermatologyIntensive care medicineInternal medicineVasculitisCancer

Abstract

fetched live from OpenAlex

BACKGROUND: Clinical trials of systemic therapies for atopic dermatitis (AD) often exclude patients based on age and comorbidities. OBJECTIVES: We conducted a scoping review of observational studies and survey of International Eczema Council (IEC) members on the treatment of AD in patients with liver disease, renal disease, viral hepatitis, HIV, or history of malignancy. METHODS: We searched MEDLINE via Ovid, Embase via Ovid, and Web of Science from inception to September 14, 2020. We mapped the available evidence on the use of cyclosporine, methotrexate, azathioprine, mycophenolate, systemic corticosteroids, and dupilumab for AD in older adults (≥65 years) and adults with the previously mentioned comorbidities. We surveyed IEC members on their preferred systemic medications for each patient population. RESULTS: We identified 25 studies on the use of systemic medications in special populations of adults with AD. Although IEC members preferred dupilumab as the first-line systemic agent across all special populations, many could not identify viable third-line systemic therapy options for some populations. CONCLUSIONS: Data on systemic therapy for AD for older adults and adults with comorbidities are limited. Although IEC members' access to systemic therapies differs geographically, expert opinion suggests that dupilumab is preferred for those patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.337
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.065
GPT teacher head0.328
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations35
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueDermatitisSame topicDermatology and Skin DiseasesFrench-language works237,207